Valuation models
price $96.54 · as of Nov 2, 2026
DCF · Perpetuity growth · 5yused61.89 – 105.6177.8924% overvaluedDCF · Perpetuity growth · 10y68.98 – 114.3185.7713% overvaluedDCF · EBITDA exit · 5y121.67 – 133.87127.6024% undervaluedDCF · EBITDA exit · 10y116.79 – 139.13127.4124% undervaluedP/E · peers79.76 – 185.26114.4816% undervaluedP/E · own history116.76 – 149.60134.7028% undervaluedPEG—117.7218% undervaluedEV/EBITDA · peers80.79 – 248.78132.4727% undervaluedEV/Revenue · peers72.11 – 215.44119.5319% undervaluedEarnings power value32.76 – 57.9142.70126% overvaluedDividend discount50.58 – 133.4276.0927% overvaluedWall St. consensus target—99.002% belowCost of capital (WACC)—7.14%—
DCF · Perpetuity growth · 5y leads for a mature, steady company — positive operating income and three years of positive free cash flow. How the headline model is chosen.
Model value · DCF · Perpetuity growth · 5y
77.89
Medtronic closed at $96.54 — overvalued by 24% vs model.
61.89the model's range105.61
DCF · Perpetuity growth · 5y leads for a mature, steady company — positive operating income and three years of positive free cash flow. From a five-year discounted cash flow.
Other models
42.70 – 134.70
Wall St. target
99.00 2% below
Above model, 1y
15 of 31 days
How it is valued
Valued asMature & stable
Low/slowing growth (~6% recent)Moderate margins (13% net margin)Pays dividendsHighly cyclical earnings
Model estimates for research reference only, not investment advice. Every model rests on assumptions that may not match what happens; how each model works is in the manual.